Works matching IS 11732563 AND DT 2022 AND VI 42 AND IP 9

Results: 8

Appropriateness of Non-vitamin K Antagonist Oral Anticoagulants Dosing According to Different Prescription Guides Used in Belgian Ambulatory Care.

Published in:

Clinical Drug Investigation, 2022, v. 42, n. 9, p. 775, doi. 10.1007/s40261-022-01190-2

By:

Delesie, Michiel;
Ballet, Arne;
Hillegeer, Cedric;
Desteghe, Lien;
Dendale, Paul;
Heidbuchel, Hein

Publication type:

Article

Safety, Tolerability, and Pharmacokinetics of Ropanicant (SUVN-911), a Novel Alpha4 Beta2 Nicotinic Acetylcholine Receptor (α4β2 nAChR) Antagonist, in Healthy Adult and Elderly Subjects.

Published in:

Clinical Drug Investigation, 2022, v. 42, n. 9, p. 747, doi. 10.1007/s40261-022-01189-9

By:

Nirogi, Ramakrishna;
Benade, Vijay;
Goyal, Vinod Kumar;
Pandey, Santosh Kumar;
Mohammed, Abdul Rasheed;
Shinde, Anil;
Dogiparti, Dhanunjay;
Ravula, Jyothsna;
Jetta, Satish;
Palacharla, Veera Raghava Chowdary

Publication type:

Article

Clinical Characteristics and Implications of Bradycardia in COVID-19 Patients Treated with Remdesivir: A Single-Center Retrospective Cohort Study.

Published in:

Clinical Drug Investigation, 2022, v. 42, n. 9, p. 763, doi. 10.1007/s40261-022-01187-x

By:

Schreiber, Ariyon;
Bauzon, Justin S.;
Batra, Kavita;
Mohammed, Salman;
Lee, Kevin;
Houshmand, Nazanin;
Pham, Uyen;
Cosme, Celica;
Inciong, Kim;
Al-Taweel, Omar;
Nasser, Keaton;
Rana, Jibran;
Sossou, Chris;
Go, Ariel;
Hawwass, Dalia;
Diep, Jimmy;
Ahsan, Chowdhury H.

Publication type:

Article

Midostaurin as the Most Likely Cause of Bilateral Adrenal Masses in a Patient with Acute Myeloid Leukemia.

Published in:

Clinical Drug Investigation, 2022, v. 42, n. 9, p. 791, doi. 10.1007/s40261-022-01186-y

By:

Schutte, Tim;
Stege, Claudia A. M.;
Smits, Mark M.;
Franssen, Laurens E.;
Donker, Marjolein L.;
de Leeuw, David C.

Publication type:

Article

Leflunomide Exposure and Teriflunomide Concentrations up to the Third Trimester of Pregnancy: A Case Report.

Published in:

Clinical Drug Investigation, 2022, v. 42, n. 9, p. 787, doi. 10.1007/s40261-022-01185-z

By:

De Klaver, Paul A. G.;
Geesink, Carolien M.;
Broen, Jasper C. A.;
Derijks, Luc J. J.

Publication type:

Article

Efficacy and Safety of a Fixed-Dose Combination of Cinnarizine 20 mg and Dimenhydrinate 40 mg in the Treatment of Patients with Vestibular Vertigo: An Individual Patient Data Meta-Analysis of Randomised, Double-Blind, Controlled Clinical Trials.

Published in:

Clinical Drug Investigation, 2022, v. 42, n. 9, p. 705, doi. 10.1007/s40261-022-01184-0

By:

Scholtz, Arne W.;
Waldfahrer, Frank;
Hampel, Regina;
Weisshaar, Gerhard

Publication type:

Article

Cost–Utility Analysis of Pharmacogenetic Testing Based on CYP2C19 or CYP2D6 in Major Depressive Disorder: Assessing the Drivers of Different Cost-Effectiveness Levels from an Italian Societal Perspective.

Published in:

Clinical Drug Investigation, 2022, v. 42, n. 9, p. 733, doi. 10.1007/s40261-022-01182-2

By:

Carta, Andrea;
Del Zompo, Maria;
Meloni, Anna;
Mola, Francesco;
Paribello, Pasquale;
Pinna, Federica;
Pinna, Marco;
Pisanu, Claudia;
Manchia, Mirko;
Squassina, Alessio;
Carpiniello, Bernardo;
Conversano, Claudio

Publication type:

Article

Pharmacokinetics of Imeglimin in Caucasian and Japanese Healthy Subjects.

Published in:

Clinical Drug Investigation, 2022, v. 42, n. 9, p. 721, doi. 10.1007/s40261-022-01181-3

By:

Fouqueray, Pascale;
Chevalier, Clémence;
Bolze, Sébastien

Publication type:

Article